Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma

Cancer Medicine

Volumn 4, Issue 10, 2015, Pages 1525-1535

  van Kempen, Pauline M W ^a   Noorlag, Rob ^a   Braunius, Weibel W ^a   Moelans, Cathy B ^a   Rifi, Widad ^b   Savola, Suvi ^b   Koole, Ronald ^a   Grolman, Wilko ^a   van Es, Robert J J ^a   Willems, Stefan M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MRC HOLLAND   (Netherlands)

Author keywords

11q13; Copy number aberrations; HPV; Lymph node metastases; Oral cavity SCC; Oropharyngeal SCC

Indexed keywords

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CCND1 GENE; CDK6 GENE; COPY NUMBER VARIATION; CTTND GENE; DISEASE FREE SURVIVAL; EGFR GENE; FADD GENE; FEMALE; FGF4 GENE; GENE; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MCCC1 GENE; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOGENE MYC; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CANCER; PIK3CA GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TP63 GENE; TUMOR SUPPRESSOR GENE; WART VIRUS; AGED; CHROMOSOME 11; CHROMOSOME ABERRATION; COMPLICATION; GENETICS; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; MOUTH TUMOR; ONCOGENE; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PERSONALIZED MEDICINE; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

CCN PROTEIN; CCND1 PROTEIN, HUMAN; CYCLIN D1; ONCOPROTEIN; TUMOR MARKER; WISP1 PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CCN INTERCELLULAR SIGNALING PROTEINS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CYCLIN D1; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; ONCOGENES; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PRECISION MEDICINE; PROTO-ONCOGENE PROTEINS; YOUNG ADULT;

EID: 85006210746     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.499     Document Type: Article

References (52)

1. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69-90.
2. Crowe, D. L., J. G. Hacia, C. L. Hsieh, U. K. Sinha, and H. Rice. 2002. Molecular pathology of head and neck cancer. Histol. Histopathol. 17:909-914.
3. Bossi, P., L. Locati, and L. Licitra. 2013. Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opin. Emerg. Drugs 18:445-459.
4. Le, Q. T., and A. J. Giaccia. 2003. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin. Cancer Res. 9:4287-4295.
5. Leemans, C. R., B. J. Braakhuis, and R. H. Brakenhoff. 2011. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11:9-22.
6. Tran, N., B. R. Rose, and C. J. O'Brien. 2007. Role of human papillomavirus in the etiology of head and neck cancer. Head Neck 29:64-70.
7. Smeets, S. J., B. J. Braakhuis, S. Abbas, P. J. Snijders, B. Ylstra, M. A. van de Wiel, et al. 2006. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25:2558-2564.
8. Klussmann, J. P., J. J. Mooren, M. Lehnen, S. M. Claessen, M. Stenner, C. U. Huebbers, et al. 2009. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin. Cancer Res. 15:1779-1786.
9. van Kempen, P. M., R. Noorlag, W. W. Braunius, I. Stegeman, S. M. Willems, and W. Grolman. 2014. Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 9:194-203.
10. van Kempen, P. M., L. van Bockel, W. W. Braunius, C. B. Moelans, M. van Olst, R. de Jong, et al. 2014. HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation. Cancer Med. 3:1185-1196.
11. Seiwert, T. Y., Z. Zuo, M. K. Keck, A. Khattri, C. S. Pedamallu, T. P. Stricker, et al. 2015. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21:632-641.
12. Ang, K. K., J. Harris, R. Wheeler, R. Weber, D. I. Rosenthal, P. F. Nguyen-Tan, et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363:24-35.
13. Masterson, L., D. Moualed, Z. W. Liu, J. E. Howard, R. C. Dwivedi, J. R. Tysome, et al. 2014. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur. J. Cancer 50:2636-2648.
14. Leusink, F. K., R. J. van Es, R. de Bree, R. J. Baatenburg de Jong, S. R. van Hooff, F. C. Holstege, et al. 2012. Novel diagnostic modalities for assessment of the clinically node-negative neck in oral squamous-cell carcinoma. Lancet Oncol. 13:e554-e561.
15. de Bree, R., R. P. Takes, J. A. Castelijns, J. E. Medina, S. J. Stoeckli, A. A. Mancuso, et al. 2014. Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. Head Neck [Epub ahead of print].
16. Noorlag, R., P. M. van Kempen, C. B. Moelans, R. de Jong, L. E. Blok, R. Koole, et al. 2014. Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer. Epigenetics 9:1220-1227.
17. van Diest, P. J. 2002. No consent should be needed for using leftover body material for scientific purposes. For. BMJ 325:648-651.
18. Rietbergen, M. M., C. R. Leemans, E. Bloemena, D. A. Heideman, B. J. Braakhuis, A. T. Hesselink, et al. 2013. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int. J. Cancer 132:1565-1571.
19. Homig-Holzel, C., and S. Savola. 2012. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn. Mol. Pathol. 21:189-206.
20. Kornegoor, R., C. B. Moelans, A. H. Verschuur-Maes, M. C. Hogenes, P. C. de Bruin, J. J. Oudejans, et al. 2012. Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res. Treat. 135:49-58.
21. Albertson, D. G. 2006. Gene amplification in cancer. Trends Genet. 22:447-455.
22. Dahlgren, L., H. Mellin, D. Wangsa, K. Heselmeyer-Haddad, L. Bjornestal, J. Lindholm, et al. 2003. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int. J. Cancer 107:244-249.
23. Braakhuis, B. J., P. J. Snijders, W. J. Keune, C. J. Meijer, H. J. Ruijter-Schippers, C. R. Leemans, et al. 2004. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J. Natl. Cancer Inst. 96:998-1006.
24. Ragin, C. C., E. Taioli, J. L. Weissfeld, J. S. White, K. M. Rossie, F. Modugno, et al. 2006. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br. J. Cancer 95:1432-1438.
25. Hafkamp, H. C., E. J. Speel, A. Haesevoets, F. J. Bot, W. N. Dinjens, F. C. Ramaekers, et al. 2003. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int. J. Cancer 107:394-400.
26. Boyer, S. N., D. E. Wazer, and V. Band. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:4620-4624.
27. Schuuring, E. 1995. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 159:83-96.
28. Weiss, M. H., L. B. Harrison, and R. S. Isaacs. 1994. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch. Otolaryngol. Head Neck Surg. 120:699-702.
29. Song, T., N. Bi, L. Gui, and Z. Peng. 2008. Elective neck dissection or "watchful waiting": optimal management strategy for early stage N0 tongue carcinoma using decision analysis techniques. Chin. Med. J. (Engl.) 121:1646-1650.
30. Okura, M., T. Aikawa, N. Y. Sawai, S. Iida, and M. Kogo. 2009. Decision analysis and treatment threshold in a management for the N0 neck of the oral cavity carcinoma. Oral Oncol. 45:908-911.
31. Monroe, M. M., and N. D. Gross. 2012. Evidence-based practice: management of the clinical node-negative neck in early-stage oral cavity squamous cell carcinoma. Otolaryngol. Clin. North Am. 45:1181-1193.
32. Thompson, C. F., M. A. St John, G. Lawson, T. Grogan, D. Elashoff, and A. H. Mendelsohn. 2013. Diagnostic value of sentinel lymph node biopsy in head and neck cancer: a meta-analysis. Eur. Arch. Otorhinolaryngol. 270:2115-2122.
33. Alkureishi, L. W., G. L. Ross, T. Shoaib, D. S. Soutar, A. G. Robertson, R. Thompson, et al. 2010. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a European multicenter trial. Ann. Surg. Oncol. 17:2459-2464.
34. Hanken, H., A. Grobe, G. Cachovan, R. Smeets, R. Simon, G. Sauter, et al. 2014. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin. Oral Investig. 18:269-276.
35. Yoshioka, S., Y. Tsukamoto, N. Hijiya, C. Nakada, T. Uchida, K. Matsuura, et al. 2013. Genomic profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. PLoS One 8:e56165.
36. Sugahara, K., Y. Michikawa, K. Ishikawa, Y. Shoji, M. Iwakawa, T. Shibahara, et al. 2011. Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma. Int. J. Oncol. 39:761-769.
37. Pathare, S. M., M. Gerstung, N. Beerenwinkel, A. A. Schaffer, S. Kannan, P. Pai, et al. 2011. Clinicopathological and prognostic implications of genetic alterations in oral cancers. Oncol. Lett. 2:445-451.
38. Michikawa, C., N. Uzawa, H. Sato, Y. Ohyama, N. Okada, and T. Amagasa. 2011. Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer. Br. J. Cancer 104:850-855.
39. Mahdey, H. M., A. Ramanathan, S. M. Ismail, M. T. Abraham, M. Jamaluddin, and R. B. Zain. 2011. Cyclin D1 amplification in tongue and cheek squamous cell carcinoma. Asian Pac. J. Cancer Prev. 12:2199-2204.
40. Prapinjumrune, C., K. Morita, Y. Kuribayashi, Y. Hanabata, Q. Shi, Y. Nakajima, et al. 2010. DNA amplification and expression of FADD in oral squamous cell carcinoma. J. Oral Pathol. Med. 39:525-532.
41. Takahashi, K. I. U. N., K. Myo, N. Okada, and T. Amagasa. 2009. Simultaneous assessment of cyclin D1 and epidermal growth factor receptor gene copy number for prognostic factor in oral squamous cell carcinomas. Oral Sci. Int. 6:8-20.
42. Uzawa, N., I. Sonoda, K. Myo, K. Takahashi, R. Miyamoto, and T. Amagasa. 2007. Fluorescence in situ hybridization for detecting genomic alterations of cyclin D1 and p16 in oral squamous cell carcinomas. Cancer 110:2230-2239.
43. Myo, K., N. Uzawa, R. Miyamoto, I. Sonoda, Y. Yuki, and T. Amagasa. 2005. Cyclin D1 gene numerical aberration is a predictive marker for occult cervical lymph node metastasis in TNM Stage I and II squamous cell carcinoma of the oral cavity. Cancer 104:2709-2716.
44. Miyamoto, R., N. Uzawa, S. Nagaoka, Y. Hirata, and T. Amagasa. 2003. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol. 39:610-618.
45. Fujii, M., R. Ishiguro, T. Yamashita, and M. Tashiro. 2001. Cyclin D1 amplification correlates with early recurrence of squamous cell carcinoma of the tongue. Cancer Lett. 172:187-192.
46. Noorlag, R., P. M. van Kempen, I. Stegeman, R. Koole, R. J. van Es, and S. M. Willems. 2015. The diagnostic value of 11q13 amplification and protein expression in the detection of nodal metastasis from oral squamous cell carcinoma: a systematic review and meta-analysis. Virchows Arch. 466:363-373.
47. Inkson, C. A., M. Ono, S. A. Kuznetsov, L. W. Fisher, P. G. Robey, and M. F. Young. 2008. TGF-beta1 and WISP-1/CCN-4 can regulate each other's activity to cooperatively control osteoblast function. J. Cell. Biochem. 104:1865-1878.
48. Chen, P. P., W. J. Li, Y. Wang, S. Zhao, D. Y. Li, L. Y. Feng, et al. 2007. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2:e534.
49. Zhang, H., H. Luo, Z. Hu, J. Peng, Z. Jiang, T. Song, et al. 2015. Targeting WISP1 to sensitize esophageal squamous cell carcinoma to irradiation. Oncotarget 6:6218-6234.
50. Nagai, Y., M. Watanabe, S. Ishikawa, R. Karashima, J. Kurashige, S. Iwagami, et al. 2011. Clinical significance of Wnt-induced secreted protein-1 (WISP-1/CCN4) in esophageal squamous cell carcinoma. Anticancer Res. 31:991-997.
51. van den Brekel, M. W., H. V. Stel, P. van der Valk, I. van der Waal, C. J. Meyer, and G. B. Snow. 1992. Micrometastases from squamous cell carcinoma in neck dissection specimens. Eur. Arch. Otorhinolaryngol. 249:349-353.
52. van den Brekel, M. W., I. van der Waal, C. J. Meijer, J. L. Freeman, J. A. Castelijns, and G. B. Snow. 1996. The incidence of micrometastases in neck dissection specimens obtained from elective neck dissections. Laryngoscope 106:987-991.